Appointment dossier — Colon Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Colon Cancer
- Bevacizumab — Review evidence · 0 positive · PMID 37217995
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07321106 · Phase 1 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer (United States)
- NCT07705334 · Phase 1 — A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors (United States)
- NCT04185272 — Butyrophilins Role in Colon Cancer (France)
- NCT04527861 — Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer (China)
- NCT06662786 · Phase 3 — A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (United States)
- NCT07612891 · Phase 1 / Phase 2 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor (China)
- NCT05086692 · Phase 1 / Phase 2 — A Beta-only IL-2 ImmunoTherapY Study (United States)
- NCT07589205 · Phase 1 — Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors (China)
- NCT06720987 · Phase 1 — A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies (United States)
- NCT05856981 · Phase 1 — Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors (United States)
- NCT06545942 · Phase 1 — Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors (United States)
- NCT06215950 · Phase 1 — A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer (China)
- NCT07782164 — Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study) (Netherlands)
- NCT05462613 · Phase 2 / Phase 3 — Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (France)
- NCT06824467 · Phase 3 — A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (United States)
- NCT02429687 · Phase 3 — TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors (China)
- NCT06824064 · Phase 2 — Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer (United States)
- NCT06425133 · Phase 2 — Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers (France)
Most-relevant first: trials that name Colon Cancer, then broader trials you may still qualify for. 1192 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT07321106), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?